NCT02917993 2026-02-09
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
Incyte Corporation
Phase 1/2 Completed
Clinical Trials
100 trialsNCT05276284 2026-01-14
TEMPLE
Rigshospitalet, Denmark
Phase 1/2 Completed
NCT04021043 2025-12-03
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT05847686 2025-11-05
Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
University of Washington
Phase 1/2 Completed
NCT04208958 2025-10-27
ConsortiumIO
Vedanta Biosciences, Inc.
Phase 1/2 Completed
NCT05091346 2025-10-24
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT03711058 2025-09-16
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT05578872 2025-08-26
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
Anaveon AG
Phase 1/2 Completed
NCT02923349 2025-08-24
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT05159388 2025-07-08
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
Servier
Phase 1/2 Completed
NCT01696565 2025-06-04
PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy
PhytoHealth Corporation
Phase 1/2 Completed
NCT02259231 2025-06-04
RTA 408 Capsules in Patients With Melanoma - REVEAL
Biogen
Phase 1/2 Completed
NCT02795988 2025-04-16
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Imugene Limited
Phase 1/2 Completed
NCT04761198 2025-03-17
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
Mereo BioPharma
Phase 1/2 Completed
NCT04666688 2025-02-12
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
PureTech
Phase 1/2 Completed
NCT04574583 2025-02-03
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01902173 2025-01-14
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT04815720 2025-01-08
KEYNOTE-B84
Vaccinex Inc.
Phase 1/2 Completed
NCT03436563 2024-11-27
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04474470 2024-09-19
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
Purple Biotech Ltd.
Phase 1/2 Completed
NCT04770688 2024-08-15
AUTOMAN
Shanghai Chest Hospital
Phase 1/2 Completed
NCT04263090 2024-05-09
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT03665285 2024-03-08
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
Phase 1/2 Completed
NCT03757858 2024-02-07
Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases
Capital Medical University
Phase 1/2 Completed
NCT04310410 2024-02-07
PRE-FURTHER
UMC Utrecht
Phase 1/2 Completed
NCT01802632 2024-01-18
AURA
AstraZeneca
Phase 1/2 Completed
NCT02030067 2023-12-06
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
Processa Pharmaceuticals
Phase 1/2 Completed
NCT02803203 2023-09-22
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT03477019 2023-01-19
Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer
St. Olavs Hospital
Phase 1/2 Completed
NCT01879085 2022-09-21
GemTax
University of Pittsburgh
Phase 1/2 Completed
NCT02494921 2022-08-31
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
University of California, San Francisco
Phase 1/2 Completed
NCT02225366 2021-12-09
Intratumoral Injections of LL37 for Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01833520 2021-02-02
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01271920 2020-12-08
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
Novartis
Phase 1/2 Completed
NCT01896856 2020-10-06
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00152906 2020-08-14
Stereotactic Radiotherapy (SRT) Liver (COLD 1)
University Health Network, Toronto
Phase 1/2 Completed
NCT01596751 2020-07-17
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
University of California, San Francisco
Phase 1/2 Completed
NCT02628132 2020-07-07
Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients
King Faisal Specialist Hospital & Research Center
Phase 1/2 Completed
NCT02077881 2020-05-28
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
NCT02221739 2020-05-11
Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
NYU Langone Health
Phase 1/2 Completed
NCT00390182 2020-03-18
GCC0319
University of Maryland, Baltimore
Phase 1/2 Completed
NCT01490996 2020-01-31
CUFOX
University of Leicester
Phase 1/2 Completed
NCT02406170 2019-10-22
REPEAT
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2 Completed
NCT00374751 2019-08-26
Effect of Samarium on the Relief of Pain Due to Vertebral Metastases
New York Presbyterian Brooklyn Methodist Hospital
Phase 1/2 Completed
NCT01567891 2019-06-27
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
Adaptimmune
Phase 1/2 Completed
NCT01206530 2019-04-18
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT02129556 2019-02-15
PANACEA
ETOP IBCSG Partners Foundation
Phase 1/2 Completed
NCT01661972 2018-10-29
X-TRAP
Duke University
Phase 1/2 Completed